Evogene (EVGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evogene (EVGN) has a cash flow conversion efficiency ratio of -0.220x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-3.79 Million ≈ $-10.16K USD) by net assets (ILA17.25 Million ≈ $46.25K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Evogene - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Evogene's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Evogene (EVGN) total liabilities for a breakdown of total debt and financial obligations.
Evogene Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evogene ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Locafy Ltd
NASDAQ:LCFY
|
-0.096x |
|
H3 Energy Limited
AU:H3E
|
0.380x |
|
ArcWest Exploration Inc
V:AWX
|
-0.006x |
|
URU METALS LTD
F:NVRA
|
N/A |
|
Rank Group PLC
LSE:RNK
|
0.130x |
|
DelphX Capital Markets Inc
V:DELX
|
0.126x |
|
Thunderstruck Resources Ltd
V:AWE
|
-0.004x |
|
Avada Group Ltd
AU:AVD
|
-0.227x |
Annual Cash Flow Conversion Efficiency for Evogene (2008–2024)
The table below shows the annual cash flow conversion efficiency of Evogene from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see EVGN market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA14.84 Million ≈ $39.78K |
ILA-19.70 Million ≈ $-52.82K |
-1.328x | -76.50% |
| 2023-12-31 | ILA28.68 Million ≈ $76.90K |
ILA-21.58 Million ≈ $-57.85K |
-0.752x | -10.52% |
| 2022-12-31 | ILA34.79 Million ≈ $93.27K |
ILA-23.68 Million ≈ $-63.48K |
-0.681x | -73.77% |
| 2021-12-31 | ILA63.42 Million ≈ $170.03K |
ILA-24.84 Million ≈ $-66.59K |
-0.392x | -14.17% |
| 2020-12-31 | ILA56.88 Million ≈ $152.50K |
ILA-19.51 Million ≈ $-52.32K |
-0.343x | -18.97% |
| 2019-12-31 | ILA60.22 Million ≈ $161.44K |
ILA-17.36 Million ≈ $-46.55K |
-0.288x | +4.32% |
| 2018-12-31 | ILA50.31 Million ≈ $134.87K |
ILA-15.16 Million ≈ $-40.65K |
-0.301x | -31.26% |
| 2017-12-31 | ILA69.38 Million ≈ $186.00K |
ILA-15.93 Million ≈ $-42.71K |
-0.230x | -71.40% |
| 2016-12-31 | ILA87.29 Million ≈ $234.02K |
ILA-11.69 Million ≈ $-31.35K |
-0.134x | -12.02% |
| 2015-12-31 | ILA103.75 Million ≈ $278.16K |
ILA-12.41 Million ≈ $-33.26K |
-0.120x | -56.06% |
| 2014-12-31 | ILA116.08 Million ≈ $311.21K |
ILA-8.89 Million ≈ $-23.85K |
-0.077x | -81.38% |
| 2013-12-31 | ILA124.75 Million ≈ $334.44K |
ILA-5.27 Million ≈ $-14.13K |
-0.042x | -7.98% |
| 2012-12-31 | ILA48.26 Million ≈ $129.38K |
ILA-1.89 Million ≈ $-5.06K |
-0.039x | -188.20% |
| 2011-12-31 | ILA48.09 Million ≈ $128.92K |
ILA2.13 Million ≈ $5.72K |
0.044x | -3.18% |
| 2009-12-31 | ILA19.34 Million ≈ $51.85K |
ILA886.00K ≈ $2.38K |
0.046x | -96.51% |
| 2008-12-31 | ILA9.61 Million ≈ $25.76K |
ILA12.61 Million ≈ $33.80K |
1.312x | -- |
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through… Read more